HiberCell
Crissy Dudgeon, Ph.D., is associate director of InVitro translational oncology at HiberCell with 20 years of cancer biology experience.
Most recently, she was a research associate at the Rutgers Cancer Institute of New Jersey and served as project leader for the pancreatic cancer metastasis program. Crissy has published more than 15 peer-reviewed research articles. She is a co-investigator on a Pancreatic Cancer Action Network Translational Research Grant, was awarded a PhRMA Foundation postdoctoral fellowship in pharmacology and toxicology and a Ruth Kirschstein F32 Fellowship Award from the National Cancer Institute during her postdoctoral research training.
She earned her Ph.D. in cell molecular biology from Johns Hopkins University and her B.S. in biochemistry and molecular biology at Penn State University.
HiberCell
2 followers
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As “the dormancy company,” they are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy.